The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with type 2 ...

The conditions under which GenAI will be developed in Denmark were outlined in the government’s revised National Strategy for Digitalisation (NSD), published in February 2024. The NSD was backed by a ...

The American Heart Association and the American Stroke Association issued guidelines Monday that also look at the effects of testosterone and estrogen on the body. Meanwhile, Eli Lilly sues three ...

Former FDA Commissioner Dr. Scot Gottlieb joins 'Squawk Box' to discuss news of Novo Nordisk's oral diabetes drug cutting ...

In Novo Nordisk’s randomized clinical trial, semaglutide reduced the risk for major adverse cardiovascular events by 14% ...